Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT. Materials and Methods The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT. Results Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976). Conclusion The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.
Abstract
Purpose Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT. Materials and Methods The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT. Results Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976). Conclusion The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.
참고문헌 (18)
- Kang MJ, "Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2019", Cancer Res Treat, 54, pp.330~344 (2022)
- Flaig TW, "Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 18, pp.329~354 (2020)
- Grossman HB, "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer", N Engl J Med, 349, pp.859~866 (2003)
- Galsky MD, "Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer", Cancer, 121, pp.2586~2593 (2015)
- Peyton CC, "Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer", JAMA Oncol, 4, pp.1535~1542 (2018)
- Ghosh A, "Recent trends in postcystectomy health-related quality of life(QoL)favors neobladder diversion : systematic review of the literature", Urology, 93, pp.22~26 (2016)
- James N, "Management of muscle invasive bladder cancer : British approaches to organ conservation", Semin Radiat Oncol, 15, pp.19~27 (2005)
- Kozak KR, "Bladder preservation for localized muscle-invasive bladder cancer : the survival impact of local utilization rates of definitive radiotherapy", Int J Radiat Oncol Biol Phys, 83, pp.e197~e204 (2012)
- Sung HH, "Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder", Investig Clin Urol, 63, pp.168~174 (2022)
- Kim H, "Neoadjuvant nivolumab plus gemcitabine", cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder, 2023, pp.55, 636~642
- Madersbacher S, "Long-term outcome of ileal conduit diversion", J Urol, 169, pp.985~990 (2003)
- Mak RH, "Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy : a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233", J Clin Oncol, 32, pp.3801~3809 (2014)
- Lee HW, "Appro-aches to clinical complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer : possibilities and limitations", Cancers(Basel), 15, pp.1323~ (2023)
- Reese AC, "The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer", Urology, 84, pp.358~363 (2014)
- Becker RE, "Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer", Eur Urol, 79, pp.364~371 (2021)
- Geynisman DM, "A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer(RETAIN)", J Clin Oncol, 41(6 Suppl), pp.438~ (2023)
- Galsky MD, "Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer : a phase 2 trial", Nat Med, 29, pp.2825~2834 (2023)
- Song SH, "The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma : a literature review of practice-changing trials", J Urol Oncol, 21, pp.154~164 (2023)